Scripps’ Scientists Re-Engineer Antibiotic To Combat Vancomycin resistant SA

A team of scientists from The Scripps Research Institute has successfully reengineered an important antibiotic to kill the deadliest antibiotic-resistant bacteria. The compound could one day be used clinically to treat patients with life-threatening and highly resistant bacterial infections.

The synthesized compound, which was described in the Journal of the American Chemical Society, is an analogue of the well-known commercial antibiotic vancomycin.  The new analogue was prepared in an elegant total synthesis, a momentous achievement from a synthetic chemistry point of view.